ORTHOPEDIC EVALUATION CENTER
www.renbaummedicalgroup.com

1 Daniel Burnham Court, Suite 365c
San Francisco, CA 94109
Phone: (800) 858-5447 Fax: (800) 858-5481

Curriculum Vitae

Richard A. Levy, M.D., FACC, Q.M.E.

Cardiovascular and Internal Medicine

Education

University of California	Berkeley	Economics	1966-1969
University of California	Los Angeles	M.D.	1969-1973

Special Studies

Coronary Prone Behavioral Research Project-Meyer Friedman Institute, SF, CA 1979 – 1984
Cardiovascular Pathology at Armed Forces Pathology Institute-National Institute of Health, Bethesda, MD 1976
Disaster Relief – Institution of Field Hospital, Guatemala, 1976

Training

Fellowship in Cardiology, Cedars Sinai Medical Center, Los Angeles, CA, 7/76-6/77
Fellowship in Cardiology, San Francisco General Hospital, 7/75-6/76
Residency in Medicine, Cedars Sinai Medical Center, Los Angeles, CA 7/74-6/75
Internship in Medicine, Cedars Sinai Medical Center, Los Angeles, CA 6/73-6/74

Licenses

California:	G27656	1974-present
BNDD:	AL6211837	1976-present

Private Practice

Solo Practice General Cardiology-Primary and Secondary Prevention, Internal Medicine
1979-present
3580 California St, #302, San Francisco, CA 94118

Certifications

Diplomat, American Board of Cardiovascular Disease, 1977 #55227
Diplomat, American Board of Internal Medicine, 1976 # 55227
Assistant- Clinical Instruction in Medicine (Cardiology) UCSF 1983-Present
American Clinical Research Professionals (ACRP)- Certification 2001
The Essentials of Becoming a Clinical Investigator
Good Clinical Practices (CGP)

Societies

Fellow, American College of Cardiology, 1991- Present
American College of Cardiology- California Chapter 1995- Present
California Medical Association, 1979- Present
San Francisco Medical Association 1979- Present
California Society of Industrial Medicine 1981- Present
San Francisco Medical Society, 1979-Present
San Francisco Heart Association, 1979-Present
Physician's Recognition Award 1983, 1987, 1992, 1998, 2005

San Francisco Heart Association Speakers Bureau 1979-1986
Board of Directors, Medical Advisor, Stonestown SF YMCA 1979-1982

Societies

Bay Area Heart Research Award, 1972-1973
Mt. Zion Hospital – Director, Cardiac Rehabilitation, 1985 – 1987
Phi Delta Epsilon Medical Fraternity, 1981-2005
Israel Heart to Heart Organization, 1990 – Present

Medical Legal Certifications

State of California – Independent Medical Examiner
State of California – Agreed Medical Examiner
State of California – Qualified Medical Examiner

Affiliations

California Pacific Medical Center, San Francisco, CA Active 1979-Present
St. Mary's Medical Center, San Francisco, CA Active 1981-Present
St Francis Memorial Hospital, San Francisco 2008-Present

Professional Activities (Medical Groups-IPAs)

1984-Present	Brown and Toland, San Francisco, Cardiology, Internal Med
1989-Present	California Pacific Medical Associates, Cardiology, Internal Med
Bay Net IPA,	San Francisco- Cardiology, Internal Med
1995-1997	Baybrook Specialists, Brae, CA- Cardiology
1994-2001	Center for Medical Reporting, Petaluma, CA-Cardiology
1993-1999	Mercy Medical Specialists, San Francisco, CA-Cardiology
	401 Diagnostic Center San Francisco, CA-Cardiology
1985-2001	San Francisco IPA – Cardiology, Internal Medicine
2001-2002	Michael M. Bronshvag, MD Inc.

Medical Device-Pharmaceutical Clinical Consulting

Treadmill Beta Test Site, Burdick, Inc., Milwaukee, WI, 1987
Board of Advisors, Advanced Coronary Intervention, Englewood CO, 1992-2000
Mentor Program, Merck, 1981-1983
Pacemaker Advisor Board, Biotronix, 1995-1996
Medical Consultant, Ancor Rehab, Vero Beach, FL, 1996-2000
Medical Consultant Vitafort Corp. Medical Product Development, Beverly Hills CA, 1990-5
Second Nature Technology, Medical Product Development, Mill Valley, CA. 1995-1997
Vicor, Inc Boca Raton, FL Advisory Board 2002 – 6 Medical Device
Board of Advisors, Non-Invasive Medical Technologies Medical Devices
Las Vegas, NV 2008-Present
Regional Advisory Boards 2004-7 GlaxoSmithKline, Reliant, AstraZeneca, MerckSchering
National Advisory Boards 2006-7 Pfizer
National Diabetic Advisory Board 2007-Present Merck
Founder and Advisor, Bright Minds Institute, San Francisco, CA 2004-Present
Advisor, Lucid Systems Inc San Francisco, CA 2006-Present

Speakers Programs

San Francisco Heart Association, 1982-1986
Merck Diabetic Education- National Diabetic Media 60 minute Infomercial 2008
Novartis 2002-Present

Speakers Programs

Merck/Schering Plough	2005-Present
Takeda	2008-Present
Boehringer-Ingelheim	2004-Present
Pfizer	2004-Present
Daiichi-Sankyo	2003-Present
AstraZeneca	2002-7
Ciba-Geigy	1986-1988
Searle	1986-1988
Squibb	1985-1988
Reliant	2002-7
Wyeth	2002-6
King	2002-6

Teaching Responsibilities

1982-Present	Assistant Clinical Professor of Medicine – University of California, SF
2004- Present	California Pacific Medical Center, SF Attending Cardiologist Cardiac Non-Invasive Lab
1977-1984	Group Leader plus Co-Author, Recurrent Coronary Prevention Project (Type A Behavior), Meyer Friedman Institute SF
1980-1983	Attending Teaching Physician – Marshal Hale Memorial Hospital (ICU)
1980-1986	Attending Teaching Physician – Mt. Zion Hospital (ICU & CCU)
1980-1985	Attending Teaching Physician – Mt. Zion Cardiology Preceptorship
1980-1985	Attending Teaching Physician – Children's Hospital Intensive Care Unit
1980-1982	Cardiac Rehabilitation Teacher – Kentfield Memorial Hospital

Publications

1. Goldberg, S., Levy, R., Siasi, B. and Betton, J. – Effects of material hypoxia and hyperoxemia upon Neonatal Pulmonary Vasculature Pediatrics 48: 528, 1971
2. Borer, JR., Harrison, L., Levy, R., Goldstein, R., and Epstein, S – Beneficial effects of Lidocaine on incidence of ventricular fibrillation during coronary occlusion in dogs. American Journal of Cardiology 37: 866,1976
3. Levy, R., Charuzi, Y. and Mandel, W – Lidocaine, a new technique for intravenous administration. Abstract in Circulation Suppl. II, Vol. 51: 11-209, 1975
4. Levy, R., Charuzi, Y. and Mandel, W. – A new technique for IV Lidocaine administration, American Journal of Cardiology 39: 1036-8, 197
5. Levy, R., Sellers, A., Mandel, W. and Okum, R. – Quinidine Pharmacokinetic in anephric and normal subjects. Presented at Western Society Clinical Research, February 1976 Abstract in Clinical Research, February 1976
6. Friedman, M., et al, Levy, R. – Feasibility of Altering Type A behavior pattern after myocardial infarction. Circulation 66: 83-92, Recurrent Coronary Prevention Project – Methods and preliminary Findings. 1982
7. Friedman, M., et al, Levy, R. – Alteration in Type A behavior and reduction in cardiac recurrences in post myocardial infarction patients Am Heart J 108-237, Vol. 108, No 2, pp. 237-248 August 1984
8. Friedman, M., et al, Levy, R. – The diagnosis and quantitative assessment of Type A behavior: Introduction and description of the videotaped structured interview. Integrative Psychiatry July – August 1984

Publications (continued…)

9. Friedman, M. et al, Levy, R. – Can the Type A behavior pattern be altered after myocardial infarction? A second year report from the Recurrent Coronary Prevention Project. PsychoSomatic Medicine Vol 46, No 4 July/August 1984
10. Friedman, M, et al, Levy, R. – Alteration of Type A behavior on cardiac recurrences in post myocardial infarction patients: Summary results of the Recurrent Coronary Prevention Project. American Heart Journal Vol 112 No 4 October, 1986
11. Friedman, M, et al, Levy, R – Effects of discontinuance of Type A behavior counseling on Type A behavior and cardiac recurrence rate of post myocardial infarction patients. American Heart Journal Vol 114 No 3 September 1986
12. Poster-Effective therapy for vasovagal syncope via myocardial contractility based pacemaker rate response-closed loop stimulation. Heart Rhythm Society Scientific Sessions, Boston, MA 2006

Hospital Panel Reader Non-Invasive Cardiology (EKG, ECHO, Treadmill, Holter, event)

1984-1998	EKG panel at Mt. Zion hospital 1-3 months per year @ 1,500/month
1982-1996	EKG interpretations for Industrial Health, Palo Alto, CA @ 5,000/year
1981-1990	EKG reading at Marshal Hale Memorial Hospital
1982-1985	Pacemaker interpretations for American Scanning Center, Inc., Berkeley, CA, (100- 200/mo)
1977-1982	EKG instructor at San Francisco General Hospital
1977-1979	EKG reading at EKG Programs, Inc. (50 – 150 daily)
1977-1979	EKG reading panel – Ralph K. Davies Medical Center
2002-Present	EKG reading California Pacific Medical Center (100-150 daily)
2004-Present	EKG reading Ralph K Davies Campus of CPMC
1995-Present	Echo Interpretations at California Pacific, Mt. Zion, Ralph K. Davies, St Mary's
1986 – 2000	Ultrascan (Mobile Ultrasound) San Francisco, CA
1981 – 1983	MEDS, (Mobile Ultrasound and Interpretation) San Francisco, CA

Medical-Legal Experience

Workers Comp— State of California AME/QME since 1985-present
Cardiology, Internal Medicine
Primary experience was AME prior to Cal SB899, 2005 reforms
Equal evaluation experience between applicants and defense
MPN Treatment- Liberty Mutual, Health First, State Comp, CCSF
Other networks pending

Personal Injury- Medical Malpractice-legal consultations
Experience-1985 to present
Small portion of active practice
Trial, deposition and consultative experience for both plantiff/defense
Asbestosis experience
Family law experience
Product/pharmaceutical/ clinical research issues
Expertise in hypertension, CHF, CAD, arrhythmias, in-patient out-patient cardiology and internal medicine issues

Clinical Pharmaceutical Research Experience:

1992 – 1993 Amlodipine-Hypertension Phase 4 Clinical Data – Pfizer

1985 – 1986 Transdermal Nitroglycerin Patch Phase 4 Clinical Data – Quality of LifStudy- CIBA - Geigy

1999 **G.D. Searle**

A Multicenter, Double-Blind, Parallel Group Study comparing the effects on renal function and the incidence of gastro-duodenal ulcer associated with Valdecoxib XXX mg and XXX mg BID with that of Naproxen XXX mg BID in patients with osteoarthritis or rheumatoid arthritis (Phase 4)

1999 **Boehringer Ingelheim Pharmaceuticals, Inc.**

Evaluation of the effectiveness of Micardis (telmisartan) in blood pressure control and quality of life in patients with essential hypertension (MICCAT) (Phase 4)

1999 **C.V Therapeutics**

Protocol CVT 3033, a double-blind, randomized, stratified, placebo-controlled, parallel study of Ranolazine SR at doses of 750 mg twice a day and 1000 mg twice a day in combination with other anti-anginal medications in patients with chronic stable angina (Phase 3)

2000 **C.V. Therapeutics**

Protocol CVT 3034, an 0pen-label, long-term, safety study of Ranolazine SR for chronic stable angina pectoris at doses of 500 mg. 750 mg and 1000 mg twice a day administered in combination with background anti-anginal therapy. (Phase 3)

2000 **AstraZeneca**

Efficacy and safety study of the oral direct thrombin inhibitor H 376/95 compared with dose-adjusted Warfarin (Coumadin®) in the prevention of Stroke and Systemic Embolic Events in patients with Atrial Fibrillation (SPORTIF V) (Phase 3)

2000 **Sepracor**

Multicenter, double blind, double-dummy, placebo and active-controlled study of Norastemizole in cardiac compromised subjects. (Phase 3)

2000 **Novartis**

Protocol CVAL 489US13 (Quality of life trial in hypertension QOLITY Study). Diovan (Phase 4)

2000 **Bristol-Myers Squibb**

Protocol CV123-228 Pravastatin Inflammation/CRP Evaluation (PRINCE) (Phase 4)]

2001 **AstraZeneca**

Protocol 4522IL/0065 Rosuvastatin A 6-week open-label, dose comparison study to evaluate the safety and efficacy of Rosuvastatin versus Atorvastatin, Cerivastatin, Pravastatin and Simvastatin in subjects with hypercholesterolemia. (STELLAR). (Phase 3)

2001 **AstraZeneca**

Protocol 4522US/0003 Rosuvstatin Open-label, 3-arm parallel-group, multi-center, phase IIIb study comparing the efficacy and safety of Rosuvastatin with Atorvastatin and Simvastatin NCEP ATP III LDL-C goals in high-risk subjects with hypercholesterolemia in the managed care setting. (SOLAR) (Phase 3)

2002 **Bertek/Kendle**

Protocol NEB-321 A double-blind, multi-center, randomized, placebo controlled, parallel group study of the efficacy and safety of Nebivolol added to existing antihypertensive treatment in patients with mild-moderate hypertension. (Phase 3)

2002 **Pfizer**

Protocol (A3841012) Clinical utility of Amlodipine/Atorvastatin to improve concomitant cardiovascular factors of hypertension and dyslipidemia (GEMIMI). (Phase 3)

2003 **Pfizer**

A multi-center, randomized, double-blind, double-dummy study evaluating the safety and efficacy of the addition of amlodipine to quinapril or losartan in the Treatment of diabetic hypertensive subjects. Protocol Identifier A0531063 (ADHERE) (Phase 4)

2003 **Novartis**

A multicenter, double-blind, randomized, parallel group study to evaluate the effects of Lotrel and Lotensin HCT on the development of diabetic nephropathy in hypertensive subjects with Type 2 diabetes mellitus and micro-albuminuria. (Phase 4)

2003 **AstraZeneca**

A 26-Week double blind, randomized, multi-center, phase IIIb, parallel group to compare the efficacy and safety of Rosuvastatin (40mg) with Atrovastain (80mg) in subjects with hypercholesterolaemia and coronary heart disease (CHD Risk) equivalents (study 4522IL/0106) (Phase 3)

2003 **Organon**

A multicenter randomized, open –label, assessor-blind, non inferiority study comparing the efficacy and safety of once-weekly subcutaneous Idraparinux (SanOrg34006) with adjusted-dose oral vitamin-K antagonists in the prevention of thrombo-embolic events in patients with atrial fibrillation. (Phase 3)

2005 **Novartis**

A six-week, randomized, double-blind, parallel-group, mulicenter study to evaluate the safety and efficacy of the combination of Aliskiren 150mg and Amlodipine 5mg compared to Amlodipine 5mg and 10mg in hypertensive patients not adequately responsive to Amlodipine 5mg. (2305) (Phase 3)

2005 **AstraZeneca**

A randomized, double-blind, placebo-controlled, multi-center, phase III study of Rosuvastain (Crestor) 20mg in the primary prevention of cardiovascular Events among subjects with low levels of LDL-cholesterol and elevated Levels of C-Reactive Protein. (phase 3)

2005 **Novartis**

A multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effects of Aliskiren on proteinuria when added to standardized Losartan therapy and optimal antihypertensive therapy in patients with hyperartension and Type 2 diabetes mellitus. (2201) (Phase 3.

2005 **Novartis**

A 28 –week, Multicenter, randomized, active, controlled, parallel group study to evaluate the effects of Diovan HCT (160/12.5mg) in comparison with hydrochlororhiazide (25mg) monotherapy for treatment of patients with hypertension, uncontrolled by hydrochorothiazide (12.5mg) monotherapy. (Val Dictate) (Phase 4)

2005 **Sanofi-Synthelabo**

A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter. (AF/AFL)(ATHENA) (Phase 3)

2005 **Novartis**

A randomized, double-blind, placebo-controlled , parallel-group, multicenter study Comparing an eight-week treatment of aliskiren 75mg, 150mg, 300mg to placebo in Patients with essential hypertension (2328) (Phase 3)

2005 **Boehringer Ingelheim**

Randomized Evaluation for Long Term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran Etexilate with Open with Open Label Warfarin for the Prevention Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Prospective, Multi-Center, Parallel-Group, Non-Inferiority Trail (RE-LY Study).(Phase 3)

2006 **Abbott**

A Multicenter, Randomized, Double-Blind, Prospective Study Comparing Safety and Efficacy Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Monotherapy in Subjects with Mixed Dyslipidemia Protocol M05- 749. (Phase 3)

2006 **Abbott**

A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with Mixed Dyslipidemia Protocol M05-758 (Phase 3)

2006 **Amgen**

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin-alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia. (Phase 3)

2008 **Schering-Plough**

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 P- TIMI 50)

2008 **Novartis**

A 10 week, randomized, double-blind, parallel group, Multi-center study to evaluate the efficacy and safety of once daily dosing of Aliskiren (300mg qd) to twice daily dosing of Aliskiraen (150mg bid) in patients with essential hypertension. (SPP100A2403)

2008 **Novartis**

A multicenter, randomized, double blind, parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen of Exforge in patients un controlled on ARB monotherapy. CVAA489AUS02.

2008 **Schering-Plough**

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With History of Atherosclerotic Disease: Secondary Prevention of Atherothrombotic Ischemic Events (TRA2 P – TIMI 50).

2008 **Cogent**

A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Protocol CG104

2009 **Takeda**

A Double Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate The Efficacy and Safety of TAK-491 When Compared with Valsartan and Olmesartan in Subjects With Essential Hypertension #01-06-TL-491-019.

2009 **Novartis**

An 8-week Multicenter, Randomized, Double-blind, Active Controlled, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren / Amlodipine / HCTZ compared to Aliskiren / Amlodipine in US Minority Patients with Stage 2 Hypertension CSPA100AUS02**.**

2009 **Takeda**

TMX-67_301 A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety and Efficacy of Febuxostat and Allopurinoll in Subjects with Cardiovascular Comorbidities, Hyperuricemia and Gout.